Literature DB >> 59787

Influenza virus subunit vaccines. II. Immunogenicity and original antigenic sin in humans.

R G Webster, J A Kasel, R B Couch, W G Laver.   

Abstract

Subunit vaccines containing hemagglutinin, neuraminidase, and nucleocapsids of A/Port Chalmers/1/73 (H3N2) influenza virus were prepared after treatment of purified virus with ammonium deoxycholate. The immunogenicity of these subunits and the response to the common and specific antigenic determinants on the hemagglutinin subunits were studied in man. The subunits were as immunogenic in man as intact inactivated influenza virus vaccine at an equivalent concentration. Booster doses of antigen did not increase the antibody responses. Intact influenza B virus vaccine did not potentiate the immune response to the type A subunits in man. Volunteers responded differently to the common and specific determinants on the hemagglutinin subunits. The predominant antibody response was to the common or cross-reacting determinants present on hemagglutinins of both A/Hong Kong/1/68 (H3N2) and Port Chalmers/73 virus. Some men who failed to produce specific antibodies to the hemagglutinin of Port Chalmers/73 virus responded to the specific determinants on the Hong Kong/68 hemagglutinin. Higher doses of the subunit vaccines (1,400 chick cell-agglutinating units) did induce antibodies to the specific determinants on the Port Chalmers/73 virus hemagglutinin as well as to the common and specific determinants on Hong Kong/68 influenza virus.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 59787     DOI: 10.1093/infdis/134.1.48

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

1.  Variable efficacy of repeated annual influenza vaccination.

Authors:  D J Smith; S Forrest; D H Ackley; A S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  A simple mechanistic explanation for original antigenic sin and its alleviation by adjuvants.

Authors:  Wilfred Ndifon
Journal:  J R Soc Interface       Date:  2015-11-06       Impact factor: 4.118

3.  Antigenic distance measurements for seasonal influenza vaccine selection.

Authors:  Zhipeng Cai; Tong Zhang; Xiu-Feng Wan
Journal:  Vaccine       Date:  2011-11-07       Impact factor: 3.641

4.  The generation of influenza outbreaks by a network of host immune responses against a limited set of antigenic types.

Authors:  Mario Recker; Oliver G Pybus; Sean Nee; Sunetra Gupta
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-25       Impact factor: 11.205

5.  Profiles of influenza A/H1N1 vaccine response using hemagglutination-inhibition titers.

Authors:  Robert M Jacobson; Diane E Grill; Ann L Oberg; Pritish K Tosh; Inna G Ovsyannikova; Gregory A Poland
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  High preexisting serological antibody levels correlate with diversification of the influenza vaccine response.

Authors:  Sarah F Andrews; Kaval Kaur; Noel T Pauli; Min Huang; Yunping Huang; Patrick C Wilson
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

7.  Investigations on strain-specific and common antigen antihemagglutinin antibodies oriented to the influenza virus H3N2 strains A/Hong Kong/1/68 and A/Port Chalmers/1/73.

Authors:  J Drescher; W Verhagen
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

8.  The antigenicity of whole virus versus subunit trivalent influenza vaccines -- a field trial in the Israel Defence Forces, 1978.

Authors:  J D Kark; M Lebiush; L Rannon; E Witztum; E Nili; R Kedem
Journal:  Med Microbiol Immunol       Date:  1981       Impact factor: 3.402

9.  Influenza 1980-1.

Authors: 
Journal:  Br Med J       Date:  1980-08-23

10.  Influenza A virus matrix protein 1-specific human CD8+ T-cell response induced in trivalent inactivated vaccine recipients.

Authors:  Masanori Terajima; John Cruz; Anita M Leporati; Laura Orphin; Jenny Aurielle B Babon; Mary Dawn T Co; Pamela Pazoles; Julie Jameson; Francis A Ennis
Journal:  J Virol       Date:  2008-07-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.